Kasim Kutay

Last updated
Kasim Kutay
Born (1965-05-13) May 13, 1965 (age 59)
Alexandria, Egypt
CitizenshipUnited Kingdom
EducationBSc. and MSc. - London School of Economics
Employer Morgan Stanley (1989–2007)

Sun Group (2007–2009) Moelis & Company (2009–2016)

Novo Holdings A/S (2016–present)
Title
Board member of
SpouseMaha Arakji Kutay
Children3

Kasim Kutay (born 13 May 1965) is a British fund manager who is the CEO of Danish Novo Holdings A/S, an investment fund that manages investments and assets for the Novo Nordisk Foundation. He holds British citizenship and resides in Denmark.

Contents

Kasim Kutay was a investment banker, focusing on the healthcare sector. [1] Kasim Kutay assumed the role of CEO at Novo Holdings A/S on September 1, 2016, following the departure of Eivind Kolding. [2] [3] [4] Kasim Kutay joined Novo Holdings A/S after more than two decades working within investment banking.

Early life and education

Kasim Kutay is a citizen of the United Kingdom. He was born in Alexandria, Egypt on 13 May 1965 to a Turkish father and Syrian mother. [3]

The family moved to Lebanon until the Lebanese Civil War broke out in 1975 where the family relocated to London, United Kingdom. [3]

Prior to studying at LSE (London School of Economics and Political Science), Kasim Kutay went to the American Community School in London. [3]

He studied at the London School of Economics and Political Science, where he attained his Master of Science in Economics in 1987. Kasim Kutay holds a BSc in Economics and an MSc in Politics of the World Economy, both from the LSE (London School of Economics and Political Science).[ citation needed ]

Career

Kasim Kutay began his career, with his first job as a graduate trainee at Morgan Stanley in 1989. [3] Kasim Kutay spent 18 years at Morgan Stanley advising mainly healthcare companies. [5]

He rose to the post of chairman of its European Healthcare Group. [4] After 18 years at Morgan Stanley, Kasim Kutay worked at a private US investment firm, Sun Group, [3] prior to joining Moelis & Company in 2009.

He joined Moelis & Company in 2009, where he worked for seven years, serving as Co-head of Europe and member of its Management Committee until he joined Novo Holdings A/S in 2016. [6] [1]

Novo Holdings A/S

Kasim Kutay was appointed CEO of Novo Holdings A/S in June 2016, succeeding Eivind Kolding.

Kasim Kutay was very familiar to Novo Holdings A/S before assuming the role of CEO, having previously advised the company over many years on both disposals and acquisitions. He has also advised several other Danish healthcare companies including William Demant and Lundbeck. [2]

Novo Holdings A/S manages approximately DKK 710 billion Danish Kroners [2] [3] (approximately $106bn) [3] worth of assets.

Philanthropy and public positions

Kasim Kutay has written on and advocated for the need for greater investment and policy changes to tackle the pandemic of antimicrobial resistance (A Plan to Avert a ‘Superbug’ Pandemic). [7]

In 2018, Novo Holdings A/S launched REPAIR, a $165 million fund solely dedicated to investing in companies researching new antibiotics (REPAIR Impact Fund · Novo Holdings launches US$165m impact fund to combat antimicrobial resistance. [8]

Kasim Kutay is an advocate for the greater adoption of biotech solutions in industry and agriculture to assist in the green transition [9] [10] and the need for a quicker bioindustrial approval process in Europe to match US timelines. Novo Holdings is an active investor in bioindustrial companies, with a portfolio of eighteen companies in the sector. [10] [11]

Kasim Kutay has been involved in the launch of Best For You, a new model of care for adolescent mental health, based at the Chelsea and Westminster Hospital (Best For You -video- CW+). [12]

Kasim Kutay has written on the need for capital markets to evolve to be more conducive to companies seeking to pursue a “stakeholder” model by restraining certain types of hostile mergers and acquisitions (Kasim Kutay (telegraph.co.uk). [13]

Kasim Kutay is a member of the board of directors at Novozymes, [14] [15] Novo Nordisk A/S, [16] Evotec SE [17] and a former board member of Convatec up until July 3 - 2018. [18] [19]

Kasim Kutay is also a charity board member of the Chelsea and Westminster NHS Foundation Trust t. [3]

Personal life

Kasim Kutay currently resides in Denmark and is married to architect Maha Arakji Kutay. [3] The couple have three children. [20]

Related Research Articles

<span class="mw-page-title-main">Novo Nordisk</span> Danish pharmaceutical company

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.

Chr. Hansen A/S is a bioscience company based in Hørsholm, Denmark. Since January 2024 together with Novozymes a part of Novonesis. The company is a supplier of bacteria cultures, probiotics, enzymes and human milk oligosaccharides. Its products are used in the production of fresh dairy, cheese, meat, seafood, fermented beverages, dairy and meat alternatives, dietary supplements, infant formula, pharmaceuticals and agricultural products. In 2021, Chr. Hansen A/S was ranked 1st on FoodTalks' Top 30 Global Probiotic Food Ingredient Companies list. Chr. Hansen owns one of the world's largest commercial bacteria collections.

<span class="mw-page-title-main">Novozymes</span> Danish Biotechnology Company

Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.

MidOcean Partners is a New York–based alternative asset management firm that specializes in mid-sized private equity and alternative leveraged investments.

Avista Capital Partners is an American private equity firm headquartered in New York City focused on growth capital and leveraged buyout investments in middle-market companies in the domestic healthcare sector.

<span class="mw-page-title-main">Manisha Girotra</span> Indian business executive (born 1969)

Manisha Girotra is an Indian business executive. She Girotra is Chief Executive Officer of Moelis India.

<span class="mw-page-title-main">GV (company)</span> Venture capital unit of Alphabet Inc.

GV Management Company, L.L.C. is a venture capital investment arm of Alphabet Inc., founded by Bill Maris, that provides seed, venture, and growth stage funding to technology companies. Founded as Google Ventures in 2010, the firm has operated independently of Google, Alphabet's search and advertising division, since 2015. GV invests in startup companies in a variety of fields ranging from the Internet, software, and hardware to life science, healthcare, artificial intelligence, transportation, cyber security and agriculture. It has helped finance more than 300 companies that include Uber, Nest, Slack, and Flatiron Health.

<span class="mw-page-title-main">Steen Riisgaard</span>

Steen Riisgaard is the former president and CEO of the Denmark-based biotech company Novozymes, the world’s largest producer of industrial enzymes. He held this position from when Novozymes was founded in a demerger from Novo Nordisk in 2000 until he left the company in 2013 when Peder Holk Nielsen became CEO.

<span class="mw-page-title-main">Moelis & Company</span> Global independent investment bank

Moelis & Company is a global investment bank that provides financial advisory services to corporations, governments, and financial sponsors. The firm advises on strategic decisions such as mergers and acquisitions, recapitalizations and restructurings and other corporate finance matters. Moelis is widely considered one of the most prestigious investment banking advisory firms and has advised on more than $4 trillion in transactions since its inception.

Kenneth D. Moelis is an American billionaire investment banker. He is also the founder, chairman and CEO of Moelis & Company, a global independent investment banking firm.

John P. Costas is an American businessman, banker, and trader. He is the former chairman and CEO of UBS Investment Bank, where he oversaw the growth of the Swiss bank's investment banking franchise globally from 2000 to 2005. From 2005 through 2007, Costas was the chairman and CEO of Dillon Read Capital Management, a UBS proprietary trading unit and alternatives management company.

<span class="mw-page-title-main">HealthTap</span> Medical group and technology company

HealthTap is a medical group and technology company delivering telehealth virtual healthcare via the web and health apps. Their customers include health consumers in the United States, health systems, insurance companies, and self-insured employers.

Arenicins are a group of antimicrobial peptides being studied to combat Gram-negative bacteria.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

<span class="mw-page-title-main">Novo Holdings A/S</span> Danish holding company

Novo Holdings A/S is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S. Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2023 was worth almost DKK 1,114 billion. Danish Kroner and is the largest charitable foundation in the world making Novo Holdings A/S a world-leading life sciences investor. Novo Holdings A/S is headquartered in Copenhagen, Denmark, with offices in San Francisco, Boston and Singapore.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">Novo Nordisk Foundation</span> International foundation for medical treatment and research

The Novo Nordisk Foundation is an international enterprise foundation focusing on medical treatment and research.

Kevin Outterson is a lawyer, a professor of law and the Austin B. Fletcher Professor Boston University School of Law (2023-present). He is also the executive director of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, a global non-profit partnership that supports companies developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections.

Kastus Technologies is an Irish multinational nanotechnology company which specialises in patented visible light activated, photocatalytic, antimicrobial coatings. The coatings prevent the growth of bacteria on the surface it has been applied to, such as ceramics, glass, and touchscreens, with no negative side effects for the end user. Founded in Dublin in 2014, Kastus’ antimicrobial coatings were in development for over 10 years as part of a collaboration with Dublin Institute of Technology and the Advanced Materials and Bio Engineering Research (AMBER) Centres.

<span class="mw-page-title-main">Lars Rebien Sørensen</span> Danish businessman

Lars Rebien Sørensen is a Danish businessman and former CEO of the pharmaceutical company Novo Nordisk and current chairman of the board at the Novo Nordisk Foundation and Novo Holdings A/S.

References

  1. 1 2 "Archived copy" (PDF). Archived from the original (PDF) on 2017-03-06. Retrieved 2017-03-05.{{cite web}}: CS1 maint: archived copy as title (link)
  2. 1 2 3 "Investment firm Novo names Moelis's Kutay as new chief executive". Bloomberg.com. 21 June 2016. Retrieved 12 January 2022.
  3. 1 2 3 4 5 6 7 8 9 10 Meddings, Sabah (2018-11-04). "Interview: biotech boss Kasim Kutay is investing billions — according to Jante". The Sunday Times . ISSN   0956-1382 . Retrieved 2018-12-10.
  4. 1 2 "After ousting former CEO, Novo A/S puts Kutay in charge of $57B investment vehicle". Fiercebiotech.com. 22 June 2016. Retrieved 5 March 2017.
  5. ↑ "Kasim Kutay: Executive Profile & Biography - Bloomberg". Bloomberg News . Retrieved 5 March 2017.
  6. ↑ "Novo A/S appoints new CEO". PharmaTimes. June 21, 2016.
  7. ↑ Kutay, David A. Ricks and Kasim (8 July 2020). "Opinion | A Plan to Avert a 'Superbug' Pandemic". Wsj.com. Retrieved 12 January 2022.
  8. ↑ "Novo Holdings launches USD 165m impact fund to combat antimicrobial resistance". Repair-impact-fund.com. 28 February 2018. Retrieved 12 January 2022.
  9. ↑ Novo Holdings YouTube Channel: A story about how biology can be harnessed to drive the green transition https://www.youtube.com/watch?v=jATd_I_a83g
  10. 1 2 MedWatch: Novo Holdings sets sights on more acquisitions in hot bioindustry sector https://medwatch.com/News/Pharma___Biotech/article13276777.ece
  11. ↑ "Biosolutions: A clear path to fighting climate change". 23 May 2022.
  12. ↑ "Best For You". Cwplus.org.uk. 15 December 2020. Retrieved 12 January 2022.
  13. ↑ "Kasim Kutay". The Daily Telegraph. June 2020. Retrieved 12 January 2022.
  14. ↑ "Board of Directors in Novozymes". Novozymes.com. Retrieved 5 March 2017.
  15. ↑ "The Novo Team". Novo.dk. Retrieved 5 March 2017.
  16. ↑ "Kasim Kutay". Archived from the original on 2017-04-09. Retrieved 2017-04-08.
  17. ↑ "Evotec SE virtual Annual General Meeting 2020 approves all proposed agenda items". Evotec.com.
  18. ↑ "03 July 2018 - Board Changes | Convatec Group". Convatecgroup.com. Retrieved 2018-11-29.
  19. ↑ "Proposed directorate changes" (PDF). Convatecgroup.com. Retrieved 12 January 2022.
  20. ↑ Novo-Holdings press release 2016.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.